Evidence map›Paper›PMID 34681266›Full record

ReviewPharmaceuticals (Basel, Switzerland)2021

Recent Developments in the Synthesis of β-Diketones.

Gonzalo de Gonzalo, Andrés R Alcántara

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 43 citations in OpenAlex.

  1. Journal of the American Chemical Society · 2026
    Article
  2. Comparative Review ofMolecules (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Review
  5. Synthesis, crystal structure and Hirshfeld surface analysis of (2-amino-benzo-thia-zole-κActa crystallographica. Section E, Crystallographic communications · 2025
    Article
  6. Seasonal Variability of Lipophilic Compounds in Oat (Journal of agricultural and food chemistry · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Gonzalo de GonzaloOrganic Chemistry Department, University of Sevilla, c/Profesor García González 2, 41012 Sevilla, Spain.ORCID 0000-0002-0863-680X
Andrés R AlcántaraDepartment of Chemistry in Pharmaceutical Sciences, Faculty of Pharmacy, Complutense University of Madrid, Plaza de Ramón y Cajal, s/n., 28040 Madrid, Spain.ORCID 0000-0003-4856-4000
Universidad Complutense de Madrid · ESUniversidad de Sevilla · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apart from being one of the most important intermediates in chemical synthesis, broadly used in the formation of C-C bonds among other processes, the β-dicarbonyl structure is present in a huge number of biologically and pharmaceutically active compounds. In fact, mainly derived from the well-known antioxidant capability associated with the corresponding enol tautomer, β-diketones are valuable compounds in the treatment of many pathological disorders, such as cardiovascular and liver diseases, hypertension, obesity, diabetes, neurological disorders, inflammation, skin diseases, fibrosis, or arthritis; therefore, the synthesis of these structures is an area of overwhelming interest for organic chemists. This paper is devoted to the advances achieved in the last ten years for the preparation of 1,3-diketones, using different chemical (Claisen, hydration of alkynones, decarboxylative coupling) or catalytic (biocatalysis, organocatalytic, metal-based catalysis) methodologies: Additionally, the preparation of branched β-dicarbonyl compounds by means of α-functionalization of non-substituted 1,3-diketones are also discussed.

Indexed as

1,3-diketonesbiocatalysisbiological activityClaisen condensationdecarboxylative couplinghydrationmetal-based catalysisorganic synthesisorganocatalysisoxidation

Identifiers

PMID34681266
PMCPMC8541089
OpenAlexW3207249422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.